The U.S. Food and Drug Administration (FDA) has extended its review of Exelixis’ experimental colorectal cancer drug combination by three months, with a decision now due by March 3, 2027. Exelixis submitted updated safety and efficacy data in response to an FDA information request, and the agency classified the submission as a major amendment. The company is seeking approval for zanzalintinib with Roche’s Tecentriq immunotherapy for a subset of adults with metastatic colorectal cancer.